Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 37 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• A Chart Review Study of Adults With Advanced NSCLCCompletedNCT05207423
• Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)Active, not recruitingNCT05206812Phase 2
• Local Radiotherapy for Residual Tumor Lesions During the First-line TreatmentCompletedNCT05205226
• Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)Active, not recruitingNCT05200481Phase 2
• Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Phase 2
• Personalized DC Vaccines in Non Small Cell Lung CancerActive, not recruitingNCT05195619Phase 1
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
• Tislelizumab as Cross-line Treatment for Advanced NSCLCStatus unknownNCT05192681Phase 2
• Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT05186974Phase 2
• Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung CancerActive, not recruitingNCT05183932
• Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCTerminatedNCT05176925Phase 2
• Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLCStatus unknownNCT05176067Not applicable
• Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung CancerWithdrawnNCT05171062Phase 1
• Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung CancerStatus unknownNCT05170581Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05170204Phase 3
• To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLCCompletedNCT05169801Phase 3
• Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLCStatus unknownNCT05167604
• Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use TreatmentCompletedNCT05167500
• Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung CarcinomaStatus unknownNCT05165355Phase 2
• Residual Disease Evaluation of Resected NSCLC by cirDNA AnalysisCompletedNCT05165160Not applicable
• Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingNCT05163249Phase 2
• A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR MutationsActive, not recruitingNCT05163028Phase 1
• A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in JapanActive, not recruitingNCT05161325
• Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Phase 4
• A Study of PRT2527 in Participants With Advanced Solid TumorsCompletedNCT05159518Phase 1
• Effect of Exercise Training in Lung CancerCompletedNCT05158530Not applicable
• [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.Active, not recruitingNCT05157659Not applicable
• Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLCStatus unknownNCT05157542Phase 1
• Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia"Status unknownNCT05157503
• RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)CompletedNCT05154344
• (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1
• Lorlatinib Continuation StudyActive, not recruitingNCT05144997Phase 4
• A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).Status unknownNCT05141786Phase 2
• A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung CancerActive, not recruitingNCT05138900Not applicable
• Neoadjuvant Immunotherapy in Advanced NSCLCStatus unknownNCT05137912
• Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid ModelStatus unknownNCT05136014
• Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknownNCT05132777Phase 2
• A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerStatus unknownNCT05132413Phase 3
• Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung CancerStatus unknownNCT05132218
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerActive, not recruitingNCT05132075Phase 3
• Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC PatientsCompletedNCT05129462
• Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain MetastasesCompletedNCT05129202
• A Study of NDI 1150-101 in Patients With Solid TumorsActive, not recruitingNCT05128487Phase 1/2
• RBN-2397 in Combination With Pembrolizumab in Patients With SCCLActive, not recruitingNCT05127590Phase 1/2
• Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung CancerActive, not recruitingNCT05127382
• HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid TumorsTerminatedNCT05124743
• A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingNCT05120349Phase 3
• IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)CompletedNCT05118334Phase 1
• Study of HA121-28 in Patients With Non-Small Cell Lung CancerStatus unknownNCT05117658Phase 2
• Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearrangedWithdrawnNCT05116618
• Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerActive, not recruitingNCT05116462Phase 3
• Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to ImmunotherapyStatus unknownNCT05111197Phase 3
• Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsCompletedNCT05110118Phase 1
• Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung CancerCompletedNCT05106374
• Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung CancerStatus unknownNCT05104281Phase 3
• Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsActive, not recruitingNCT05103605
• HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid TumorsStatus unknownNCT05102214Phase 1/2
• Managed Access Programs for LDK378, CeritinibNo longer availableNCT05100134
• Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersTerminatedNCT05099549Phase 1/2
• Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLCStatus unknownNCT05098990Phase 4
• Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3
• Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLCWithdrawnNCT05094544Not applicable
• A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Phase 1/2
• Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer PatientsStatus unknownNCT05094167Not applicable
• Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck CancersActive, not recruitingNCT05091190Not applicable
• Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung CancerTerminatedNCT05088967Phase 1
• Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)Status unknownNCT05085054Phase 2
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsTerminatedNCT05084859Phase 1
• A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsCompletedNCT05082610Phase 1
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
• Feasibility of Radioisotope-guided Excision of Mediastinal Lymph Nodes in Patients With Non-small Cells Lung CarcinomaStatus unknownNCT05072561Not applicable
• Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.CompletedNCT05068427Phase 2
• A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingNCT05068102Phase 1
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 MutationStatus unknownNCT05065398Phase 2
• Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedNCT05062980Phase 1
• This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.TerminatedNCT05061940
• A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursActive, not recruitingNCT05057013Phase 1/2
• Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLCStatus unknownNCT05055583Phase 2
• Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLCActive, not recruitingNCT05055167Phase 2
• Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)Active, not recruitingNCT05049044
• A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsActive, not recruitingNCT05048797Phase 3
• A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05047250Phase 3
• Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung CancerWithdrawnNCT05045404Phase 2
• A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and CyprusCompletedNCT05034926
• Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung CancerStatus unknownNCT05034055Phase 2
• Predictive Assay for Decision Making in Adjuvant TherapyTerminatedNCT05032352
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabActive, not recruitingNCT05029882Phase 1
• Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With DurvalumabStatus unknownNCT05027165
• Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer PatientsCompletedNCT05023746
• Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyWithdrawnNCT05022394Phase 1/2
• SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05020769Phase 2/3
• SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.Active, not recruitingNCT05020457Phase 2
• Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung CancerActive, not recruitingNCT05020275
• Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerStatus unknownNCT05016544Phase 1/2
• Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
• Alectinib in Neo-adjuvant Treatment of Stage III NSCLCActive, not recruitingNCT05015010Phase 2
• Dupilumab_Metastatic NSCLCActive, not recruitingNCT05013450Phase 1/2
• Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesActive, not recruitingNCT05012254Phase 2
• Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3
• A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaActive, not recruitingNCT05009329Phase 1/2

← Carcinoma, Non-Small-Cell Lung overview